

Special Issue

Feature Papers of Epidemiology and Vaccines 2023

Message from the Guest Editor

As Section Editor-in-Chief of *Epidemiology*, I am pleased to announce the Special Issue "Feature Papers of Epidemiology and Vaccines 2023". This issue aims to enhance the impact of the interactions and effects of vaccines (and vaccination programs) on the occurrence of vaccine-preventable diseases. In this Special Issue, we will collect articles from top researchers describing new approaches or new cutting-edge developments in the fields of infectivity, vaccine efficacy and effectiveness, vaccine failure, herd immunity, herd effect, epidemiological transfer, and disease modeling of various epidemics. Moreover, this issue will also consider the viewpoints of major stakeholders, including decision makers, immunization program managers, public health experts, pediatricians, family doctors, and other experts/individuals involved in the provision of immunization services and those who conduct research on awareness and behaviors surrounding vaccine epidemiology, as well as in other relevant scientific fields. We welcome the submission of manuscripts from Editorial Board Members and from outstanding scholars invited by the Editorial Board and the Editorial Office.

Guest Editor

Prof. Dr. Giuseppe La Torre
Department of Public Health and Infectious Diseases, Sapienza
University of Rome, 00161 Rome, Italy

Deadline for manuscript submissions

closed (15 January 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/168865

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).